Trial Profile
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 15 Mar 2024
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Clofarabine; Cyclophosphamide; Cytarabine; Cytarabine; Cytarabine; Daunorubicin; Dexamethasone; Dexamethasone; Doxorubicin; Etoposide; Folinic acid; Folinic acid; Hydrocortisone sodium succinate; Mercaptopurine; Methotrexate; Methotrexate; Pegaspargase; Prednisone; Prednisone; Tioguanine; Vincristine
- Indications CNS cancer; Leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma; Testicular cancer
- Focus Therapeutic Use
- 12 Dec 2023 Results assessing response of Dasatinib following induction of patients with ABL-class fusion B-ALL, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 26 Sep 2023 Planned End Date changed from 27 Jan 2024 to 22 Sep 2024.
- 28 Jan 2023 Planned End Date changed from 31 Dec 2023 to 27 Jan 2024.